Biogen and Bio-Thera enter a licencing agreement
Biogen and Bio-Thera enter a licencing agreement
By Daniel Scott on January 27, 2022
Biogen and Bio-Thera Solutions have signed an agreement to develop, manufacture and commercialise the anti-interleukin-6 receptor monoclonal antibody BAT1806.BAT1806 is a proposed biosimilar referencing Actemra....
Reversing Balding is Becoming Priority for Biotech
Reversing Balding is Becoming Priority for Biotech
By Daniel Scott on January 21, 2022
Due to both stress and the aftereffects of COVID 19, hairlines have receded faster than usual during the pandemic. Many people suffer increased hair shedding...
Biotech Networks opens New Hubs during the J.P. Morgan Conference Week
Biotech Networks opens New Hubs during the J.P. Morgan Conference Week
By Daniel Scott on January 17, 2022
Biotech Networks, which has been connecting life science workers since 2008, is expanding its footprint in the United States by creating communities in the Pacific...
Houston, Dallas, and Austin, to become a Biotech Triangle
Houston, Dallas, and Austin, to become a Biotech Triangle
By Daniel Scott on January 12, 2022
Texas business leaders seek to establish a Biotech Triangle — a three-sided magnet for innovators and investors in industries ranging from medical devices and clinical...
Univercells Acquires Biotechnology Firm SynHelix
Univercells Acquires Biotechnology Firm SynHelix
By Daniel Scott on January 10, 2022
Univercells S.A. has acquired SynHelix, which aims to debottleneck biotherapeutics expansion by providing a scalable, robust, and automated DNA synthesis technology that develops extended DNA...

Sanofi and Regeneron

Posts tagged as “Sanofi and Regeneron”

GSK and IP Experts Warn that the Supreme Court’s Decision Jeopardizes Drug Innovation

By Daniel Scott on December 27, 2021

In its attempt for the US Supreme Court to intervene in a long-running dispute with Sanofi and Regeneron Pharmaceuticals Inc. over the destiny of Amgen’s…

Trust your Gut When it Comes to Sugar Intake
Trust your Gut When it Comes to Sugar Intake
By Mark Battle on January 26, 2022
The new study asks your gut to tell you the difference between natural Sugar Intake and an artificial sweetener; it may be right. The new...
CIO 5 Year Plans Approach Emerging Technology
CIO 5 Year Plans Approach Emerging Technology
By Mark Battle on January 25, 2022
Precision medicine, described by the Precision Medicine Initiative as "an emerging Approach for disease treatment and prevention that takes into account individual variability in genes,...
Severe COVID-19 Neurological Symptoms Highlight the Need for Research
Severe COVID-19 Neurological Symptoms Highlight the Need for Research
By Mark Battle on January 24, 2022
SARS-CoV-2 was initially identified as a respiratory virus, but it can affect the entire body, including the nervous system. Avindra Nath, M.D., clinical director of...
Abbott Unveils New Line Of Consumer Biosensors Based On Diabetes Monitoring Tech
Abbott Unveils New Line Of Consumer Biosensors Based On Diabetes Monitoring Tech
By Mark Battle on January 22, 2022
Consumer wearable devices currently available in the market can gather only limited health data and comprehensive devices that are sold in the market require prescription...
Less than 20% of Diabetes Patients Managing Heart Disease Risk
Less than 20% of Diabetes Patients Managing Heart Disease Risk
By Mark Battle on January 15, 2022
Fewer than 1 in 5 adults with Type 2 Diabetes in the U.S. successfully manage their heart disease risk. The study was published on Jan....